Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,262 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Arterial Occlusion Clear all
Not listed Not applicable Interventional

Non-invasive Point-of-care Diagnosis Using Machine Learning and Signal Analytics to Transform Early Detection of Heart Disease

NCT03864081
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Phase Signal Recorder
Device
Lead sponsor
Analytics For Life
Industry
Eligibility
21 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cumming, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 27, 2026, 6:52 AM EDT
Terminated No phase listed Observational

Cardiovascular Disease Screening

NCT00483951
View directory record Official record
Conditions
Congenital Heart Disease, Atherosclerosis, Myocardial Ischemia, Myocardial Infarction, Acquired Heart Disease
Interventions
Toshiba Aquilion ONE CT, SWiemens MRI scanner
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
1,325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents

NCT01319812
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease
Interventions
Astron Stents, Pulsar Stents
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
33
States / cities
Fremont, California • New Haven, Connecticut • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT05355402
View directory record Official record
Conditions
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 27, 2026, 6:52 AM EDT
Terminated No phase listed Observational

Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation

NCT02007967
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 27, 2026, 6:52 AM EDT
Active, not recruiting No phase listed Observational

Risk Factors and Outcomes of Ischemic Stroke Associated With Tandem or Isolated Cervical Artery Occlusion in Anterior and Posterior Circulation

NCT06965036
View directory record Official record
Conditions
Acute Ischemic Stroke Related to Tandem Occlusion, Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion
Interventions
Not listed
Lead sponsor
Azienda Unità Sanitaria Locale della Romagna
Other
Eligibility
Not listed
Enrollment
2,880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Not applicable Interventional Results available

Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease

NCT01983826
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Sodium Nitrate, Placebo
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Phase 4 Interventional

Semaglutide Treatment On Coronary Progression

NCT03985384
View directory record Official record
Conditions
Type 2 Diabetes, Coronary Artery Disease
Interventions
Semaglutide 2 MG/1.5 ML Subcutaneous Solution, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

NCT01890434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 27, 2026, 6:52 AM EDT
Not listed Not applicable Interventional

External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality

NCT02054416
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
ArtAssist© Device
Device
Lead sponsor
Temple University
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Transparent Elasticized Adhesive Occlusive Compression Bandage for Use as an Arterial Tourniquet

NCT02592655
View directory record Official record
Conditions
Hemorrhage, Vascular Injury
Interventions
Pneumatic Tourniquet, One Windlass Tourniquet, Two Windlass Tourniquets, Tourniquet Tape 5 cm, Tourniquet Tape 10 cm
Device
Lead sponsor
Marcus Migura
Individual
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Phase 2 Interventional

Reduction of Triglycerides in Women on Hormone Replacement Therapy

NCT00023543
View directory record Official record
Conditions
Cardiovascular Diseases, Atherosclerosis, Postmenopause, Heart Diseases
Interventions
Diet, fat-restricted, Exercise
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
52 Years to 60 Years · Female only
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Phase 2 Interventional

Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI

NCT00715455
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
REG1, Unfractionated Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Indianapolis, Indiana • Detroit, Michigan • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 27, 2026, 6:52 AM EDT
Recruiting Not applicable Interventional

BEETroot Juice to Reverse Functional Impairment in PAD

NCT05624125
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Beetroot juice, Placebo
Other
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Not applicable Interventional Results available

Comparing TR Band to Statseal in Conjunction With TR Band

NCT03028025
View directory record Official record
Conditions
Arterial Occlusion, Angina Pectoris, Cardiovascular Diseases, Atherosclerosis, Hematoma, Anticoagulant-Induced Bleeding, Coronary Artery Disease
Interventions
StatSeal, TR Band
Device
Lead sponsor
VA Long Beach Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 27, 2026, 6:52 AM EDT
Recruiting No phase listed Observational

Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status

NCT06009276
View directory record Official record
Conditions
Heart Failure, Systolic, Heart Failure, Diastolic, Peripheral Arterial Disease, Overweight and Obesity
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 27, 2026, 6:52 AM EDT
Recruiting Not applicable Interventional

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

NCT07704918
View directory record Official record
Conditions
Melanoma
Interventions
Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Phase 2Phase 3 Interventional

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

NCT00055510
View directory record Official record
Conditions
Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions
BO-653
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 6:52 AM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Not applicable Interventional Results available

Stress CT Perfusion in Patients With Chest Pain

NCT01969916
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 27, 2026, 6:52 AM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 6:52 AM EDT
Terminated No phase listed Observational

Use of Magnetocardiography in Evaluation of Patients Going for Cardiac Catheterization

NCT04044391
View directory record Official record
Conditions
Acute Coronary Syndrome, Coronary Artery Stenosis, Myocardial Ischemia
Interventions
CardioFlux Magnetocardiograph
Diagnostic Test
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 27, 2026, 6:52 AM EDT
Completed Phase 2Phase 3 Interventional

TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent

NCT00292474
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
percutaneous coronary intervention
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 27, 2026, 6:52 AM EDT
Recruiting No phase listed Observational

Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions

NCT06676046
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 27, 2026, 6:52 AM EDT